www.obroncology.com
Open in
urlscan Pro
13.224.198.44
Public Scan
Submitted URL: http://bulkmailtr.obroncology.com/ls/click?upn=MB8dCLJdh8OHRqxHymwgvdYFqatqRvi-2B-2FWL5OVcEPbzgkh9oN41SyRSFl5QX5UIdaUzSrWj8iGsaVqM...
Effective URL: https://www.obroncology.com/article/asco-attendees-call-for-mask-mandate-amid-rising-covid-19-numbers?ap=352&vhid=VH0530221417
Submission: On June 03 via manual from US — Scanned from DE
Effective URL: https://www.obroncology.com/article/asco-attendees-call-for-mask-mandate-amid-rising-covid-19-numbers?ap=352&vhid=VH0530221417
Submission: On June 03 via manual from US — Scanned from DE
Form analysis
3 forms found in the DOM<form class="nav-search-form NavSearchForm_nav-search-form__2CvyZ" autocomplete="off">
<div class="form-wrap">
<div class="input-wrap static-label search-wrap"><button type="button" tabindex="-1" class="clear-search" aria-label="clear search"><svg class="remedy-icon" xmlns="http://www.w3.org/2000/svg" color="currentColor" fill="currentColor"
overflow="hidden" style="display:inline-block;stroke:none;fill:currentColor;width:1em;height:1em" viewBox="0 0 24 24" data-testid="times-icon">
<path
d="m21.57 23.594-9.567-9.664-9.568 9.664a1.329 1.329 0 0 1-1.913 0 1.368 1.368 0 0 1-.396-.965c0-.377.152-.718.397-.965l9.562-9.666L.523 2.34a1.376 1.376 0 0 1 0-1.936A1.335 1.335 0 0 1 2.436.402l9.568 9.664L21.566.402c.245-.247.583-.399.957-.399.375 0 .713.152.957.399a1.376 1.376 0 0 1 0 1.936l-9.568 9.66 9.568 9.665c.245.248.396.589.396.965 0 .377-.151.718-.396.965a1.328 1.328 0 0 1-1.914 0l.005.001Z">
</path>
</svg></button><input type="text" aria-label="search" id="search" name="q" required="" value=""><label for="search">What can we help you find?</label></div><span></span><button type="submit" class="btn btn search-btn" disabled=""
aria-label="search"><span class="util-show-after-tablet-portrait">search</span><span class="util-hide-after-tablet-portrait"><svg class="remedy-icon" xmlns="http://www.w3.org/2000/svg" color="currentColor" fill="currentColor" overflow="hidden"
style="display:inline-block;stroke:none;fill:currentColor;width:1em;height:1em" viewBox="0 0 24 24">
<path
d="M3.008 10.508v-.074a7.428 7.428 0 0 1 7.504-7.426h-.004.074a7.428 7.428 0 0 1 7.427 7.427v.077-.004.074a7.428 7.428 0 0 1-7.428 7.427h-.077.004-.074a7.428 7.428 0 0 1-7.427-7.428v-.077.004Zm18.45 13.05a1.485 1.485 0 0 0 2.1-2.1l-4.65-4.65a10.202 10.202 0 0 0 2.1-6.224v-.081.004-.065C21.008 4.68 16.334.007 10.572.007h-.068.004-.065C4.679.007.008 4.679.008 10.442v.069-.004.064c0 5.764 4.672 10.436 10.435 10.436h.068-.003.076c2.35 0 4.517-.79 6.247-2.118l-.024.018 4.65 4.65Z">
</path>
</svg></span></button>
</div>
</form>
POST
<form class="newsletter-form NewsletterForm_newsletter-form__1hbGR GlobalFooter_remedium-footer-form__3HjtQ" novalidate="" method="post" autocomplete="on"><input type="hidden" name="group[3717][512]" id="mce-group[3717]-3717-14" value="512">
<div class="input-wrap static-label"><input type="email" aria-label="email address" id="email" name="email" placeholder="Enter your email" required="" pattern="^[a-zA-Z0-9._%+-]+@[a-zA-Z0-9.-]+\.[a-zA-Z]{2,}$" value="" autocorrect="off"><label
for="email">email address<span aria-hidden="true">required</span></label></div><input type="submit" class="btn btn-secondary" value="sign up">
</form>
POST
<form class="newsletter-form NewsletterForm_newsletter-form__1hbGR GlobalFooter_remedium-footer-form__3HjtQ" novalidate="" method="post" autocomplete="on"><input type="hidden" name="group[3717][512]" id="mce-group[3717]-3717-14" value="512">
<div class="input-wrap static-label"><input type="email" aria-label="email address" id="email" name="email" placeholder="Enter your email" required="" pattern="^[a-zA-Z0-9._%+-]+@[a-zA-Z0-9.-]+\.[a-zA-Z]{2,}$" value="" autocorrect="off"><label
for="email">email address<span aria-hidden="true">required</span></label></div><input type="submit" class="btn btn-secondary" value="sign up">
</form>
Text Content
Öffnet in einem neuen Fenster Öffnet eine externe Website Öffnet eine externe Website in einem neuen Fenster <!---->Schließen Sie diesen Dialog<!----> Auf dieser Website werden Daten wie Cookies gespeichert, um wichtige Funktionen der Website sowie Marketing, Personalisierung und Analyse zu ermöglichen. Sie können Ihre Einstellungen jederzeit ändern oder die Standardeinstellungen übernehmen. Sie können dieses Banner schließen, um nur mit essenziellen Cookies fortzufahren. Datenspeicherungsrichtlinie Einstellungen verwalten Alle akzeptieren Alles ablehnen <!---->Schließen Sie die Cookie-Einstellungen<!----> Newsletters * Cancer Types * Conferences * Expert Insights * Business & Policy * * On This Page What can we help you find? search Cancer Types * Acute Myelogenous Leukemia (AML) * Bladder Cancer * Breast Cancer * Chronic Lymphocytic Leukemia (CLL) * Colorectal Cancer * Hepatocellular Carcinoma (HCC) * Lung Cancer * Multiple Myeloma * Non-Hodgkin's Lymphoma (NHL) * Ovarian Cancer * Prostate Cancer * Renal Cell Carcinoma (RCC) * All Cancer Types Conferences * ASCO Conference Coverage * ASCO GI Conference Coverage * ASCO GU Conference Coverage * ASH Conference Coverage * COA Conference Coverage * ESMO Conference Coverage * SABCS Conference Coverage * SNO Conference Coverage * All Conference Coverage Expert Insights * Case Studies * Clinical Roundtables * Journal Scans * Leading Thoughts * Peer-Spectives Podcast * Video Center Business & Policy * Oncology Business * Policy and Value * OBR Radar * COA Conference Coverage * AMCCBS Conference Coverage SIGN UP FOR OUR NEWSLETTERS! email addressrequired FOLLOW US! -------------------------------------------------------------------------------- ABOUT * About Us * Editorial Board * Contact Us * Training * Privacy Policy * Terms of Use * Advertising Policy * Advertise With Us * Remedy Health Media Brands * Do Not Sell My Info * Cookie Preferences REMEDY HEALTH SITES * Patient Power * EndocrineWeb Pro * Practical Pain Management Pro * Psycom Pro * SpineUniverse Pro * TheBody Pro -------------------------------------------------------------------------------- remedy-logo-rgb© 2022 Remedy Health Media, LLC. All rights reserved. COVID-19 ASCO Conference Coverage ASCO ATTENDEES CALL FOR MASK MANDATE AMID RISING COVID-19 NUMBERS–UPDATED May 25, 2022 Marcia Frellick Independent Healthcare Journalist Update, 5/25/22: As of May 24, the American Society of Clinical Oncology says that masks are “expected” at its annual meeting when attendees are indoors and are not eating, drinking, or presenting. A strong recommendation to wear masks, rather than a mandate, at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago is drawing pleas on social media from some attendees for conference organizers to strengthen policies. ASCO states that for the meeting June 3-7, masks are strongly recommended, but the meeting organizers “will not require masks inside McCormick Place unless required under Illinois or Chicago guidelines or unless CDC community levels are high.” Guidance also says that proof of vaccination will be required. Negative rapid antigen or PCR COVID-19 tests within 48 hours of entrance to the first session are required, though the policy states test results will not be checked. Haley A. Moss, MD, a gynecologic oncologist at Duke University School of Medicine in Durham, North Carolina, said given worries surrounding COVID-19 she wasn’t originally planning to go to ASCO but changed her mind when she was asked to speak. Now, she said, she worries about that decision as she sees case numbers trending up. “From my experience, even in the medical community, ‘strongly encouraged’ means about 50% of the people aren’t going to wear masks,” she said, adding that she wants ASCO to mandate them. “I’m not worried about getting COVID. I’m worried about coming home from ASCO on Monday night and giving it to my 10-month-old or my two-year-old.” Manali Patel, MD, assistant professor of oncology at Stanford University in Palo Alto, California, started circulating a letter to colleagues last week asking for support for a mask mandate at the meeting. Dr. Patel said there were 110 signatures at last count. “I’m sad that we have to ask. I’m sad that this is even a question,” she said. She said she has gotten support in response to her letter but also backlash from some oncologists who say such a mandate is not necessary. “We see what’s happening in the clinic. COVID is not over,” she said. “This is not a political issue; this is a medical issue. And we need to take the reins back.” Julia Maués, a patient advocate living with metastatic breast cancer, tweeted: “I am confident most people will DO NO HARM to patients w cancer & [wear masks] but it should be a requirement.” She said she and others are speaking with ASCO leaders, and she is hopeful they will change policy and mandate masks. She is asking other patients and patient advocates to sign a letter asking that masks be required. Maués reported that the letter had 78 signatures. “We all want the same thing: For the meeting to be successful and people to be safe,” she said. ASCO declined to comment specifically to OBR about the stated policies, but a media spokesperson referenced an updated communication posted May 19 on their website: “On site in Chicago, ASCO is following health and safety protocols consistent with or exceeding current World Health Organization and Centers for Disease Control public health guidelines and local health ordinances. Highly visible signage throughout the meeting space will serve to remind attendees of ASCO’s health and safety protocols. “While Chicago is currently at medium levels of community transmission and masking is not required under state or local guidelines, this may change by the time of the meeting. Presently, ASCO strongly urges attendees to wear medical-grade masks and will provide them free of charge on site.” Let us know if you will be wearing a mask at ASCO. Dr. Moss, Dr. Patel, and Maués declared no relevant financial relationships. Notes: This article was originally published May 20, 2022 and most recently updated May 25, 2022. RELATED MelanomaJUN 2 RISK OF SKIN CANCER DEPENDS ON GENETICS AS WELL AS SUN EXPOSURE, SAYS NEW STUDY Source: Forbes LymphomaJUN 2 PEDIATRIC LYMPHOMA TRIAL AND STUDY OF FLT3 INHIBITOR FOR LEUKEMIA HIGHLIGHT ROSWELL PARK RESEARCH AT ASCO22 Source: RPCCC DiagnosticsJUN 2 PIONEERING STUDIES PROVIDE NEW OPTIONS FOR PATIENTS WITH ADVANCED CANCERS, PARTICULARLY THROUGH IMMUNOTHERAPY, NEW TARGETED THERAPIES AND GENOMICS THROUGH NGS AND LIQUID BIOPSIES Source: Hackensack Meridian Health Acute Myelogenous Leukemia (AML)JUN 1 SERVIER TO SHOWCASE GROWING ONCOLOGY PORTFOLIO AT THE ASCO AND EHA 2022 ANNUAL MEETINGS Source: Yahoo! Finance SIGN UP FOR OUR NEWSLETTERS! email addressrequired FOLLOW US! -------------------------------------------------------------------------------- ABOUT * About Us * Editorial Board * Contact Us * Training * Privacy Policy * Terms of Use * Advertising Policy * Advertise With Us * Remedy Health Media Brands * Do Not Sell My Info * Cookie Preferences REMEDY HEALTH SITES * Patient Power * EndocrineWeb Pro * Practical Pain Management Pro * Psycom Pro * SpineUniverse Pro * TheBody Pro -------------------------------------------------------------------------------- remedy-logo-rgb© 2022 Remedy Health Media, LLC. All rights reserved. Start Survey